Tramadol is absolutely contraindicated in patients with Parkinson's disease who are taking MAO-B inhibitors such as selegiline or rasagiline.
Direct Contraindication from FDA Drug Labeling
The FDA-approved prescribing information for rasagiline explicitly states that tramadol is contraindicated for use with MAO-B inhibitors due to the risk of serotonin syndrome 1. The drug label specifies that at least 14 days must elapse between discontinuation of rasagiline and initiation of tramadol 1.
Mechanism and Risk
The contraindication exists because:
- Tramadol has dual serotonergic activity through serotonin reuptake inhibition in addition to its weak mu-opioid receptor agonism 2
- MAO-B inhibitors like rasagiline and selegiline can precipitate serotonin syndrome when combined with serotonergic agents 1
- Serotonin syndrome is a potentially fatal reaction that has been specifically reported with the combination of tramadol and MAO-B inhibitors 1, 3
Clinical Guidelines Reinforce This Warning
Multiple NCCN cancer pain guidelines consistently warn that tramadol should be used with caution or avoided in patients taking monoamine oxidase inhibitor-like medications due to risk of serotonin syndrome 2, 4, 2, 4. While these guidelines address cancer pain management, the pharmacologic interaction applies universally to all patient populations.
Critical Distinction for Parkinson's Disease Patients
If the patient is NOT taking an MAO-B inhibitor, tramadol is not contraindicated solely based on the Parkinson's disease diagnosis itself. However, there are important caveats:
- Recent research suggests tramadol may be associated with increased risk of parkinsonism and related movement disorders (aOR 2.04,95% CI 1.57-2.64) 5
- This risk should be weighed against potential benefits in PD patients not on MAO-B inhibitors
Practical Algorithm
For PD patients on selegiline or rasagiline:
- Do not prescribe tramadol under any circumstances
- If tramadol is already prescribed, discontinue immediately
- Wait minimum 14 days after stopping rasagiline before considering tramadol 1
- Alternative opioids: morphine, oxymorphone, hydromorphone, or oxycodone are safer choices 2
For PD patients NOT on MAO-B inhibitors:
- Tramadol is not absolutely contraindicated but should be used cautiously
- Consider alternative opioids given the potential association with worsening movement disorders 5
- If tramadol is used, monitor closely for emergence or worsening of parkinsonian symptoms
Common Pitfall to Avoid
Do not assume that because selegiline and rasagiline are "selective" MAO-B inhibitors at therapeutic doses that the interaction risk is negligible. The FDA contraindication is absolute and applies to all MAO-B inhibitors, including the selective ones 1. The selectivity diminishes at higher doses, and even at recommended doses, the serotonin syndrome risk with tramadol remains clinically significant 1.